Saltoro Capital’s Travere Therapeutics TVTX Stock Holding History

Saltoro Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-45,950	Closed	-$966K	–	62
2022 Q4	$966K	Buy	+45,950	New	+$974K	0.77%	21

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Saltoro Capital's TVTX Position: Q1 2023 in Review

Saltoro Capital sold out of Travere Therapeutics (TVTX) in Q1 2023, closing a stake of 45,950 shares — an estimated $966K sold.

Saltoro Capital first reported a position in TVTX in Q4 2022 and held it in 1 quarter. The position peaked at $966K in Q4 2022. 174 funds tracked by Wall St. Rank hold TVTX as of Q1 2023.

Saltoro Capital reported no remaining Travere Therapeutics position as of Q1 2023 after selling out during the quarter.
Saltoro Capital sold 45,950 Travere Therapeutics shares in Q1 2023, an estimated $966K.
Saltoro Capital first reported a position in Travere Therapeutics in Q4 2022 and held it in 1 quarter.
Saltoro Capital's Travere Therapeutics position peaked at $966K in Q4 2022.
174 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2023.

Based on Saltoro Capital's 13F filing for Q1 2023, filed 10 May 2023.